Screening and preliminary identification of long non-coding RNAs critical for osteogenic differentiation of human umbilical cord mesenchymal stem cells

Xiao Zheng, Shuaiqi Gan, Cheng Su, Zheng Zheng, Yihan Liao, Jingjing Shao, Zhimin Zhu, and Wenchuan Chen

ABSTRACT

Human umbilical cord mesenchymal stem cells (hUCMSCs) are attractive therapeutic cells for tissue engineering to treat bone defects. However, how the cells can differentiate into bone remains unclear. Long non-coding RNAs (lncRNAs) are non-coding RNAs that participate in many biological processes, including stem cell differentiation. In this study, we investigated the profiles and functions of lncRNAs in the osteogenic differentiation of hUCMSCs. We identified 343 lncRNAs differentially expressed during osteogenic differentiation, of which 115 were upregulated and 228 were downregulated. We further analyzed these lncRNAs using bioinformatic analyses, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. GO and KEGG pathway analysis showed that 'intracellular part' and 'Phosphatidylinositol signaling system' were the most correlated molecular function and pathway, respectively. We selected the top 10 upregulated lncRNAs to construct six competing endogenous RNA networks. We validated the impact of the lncRNA H19 on osteogenic differentiation by overexpressing it in hUCMSCs. Overall, our results pave the way to detailed studies of the molecular mechanisms of hUCMSC osteogenic differentiation, and they provide a new theoretical basis to guide the therapeutic application of hUCMSCs.

Introduction

Bone defects caused by tumor resection, infection or trauma are common [1]. Cell-based tissue engineering using mesenchymal stem cells (MSCs) has emerged as a new approach for bone repair and reconstruction [2]. MSCs are cells capable of self-renewing and differentiating along multiple lineages. Bone marrow mesenchymal stem cells (BMSCs) are one of the most studied types of MSCs and have shown promising clinical results for regenerative bone therapy [3]. However, human BMSCs (hBMSCs) are not always applicable in the clinical setting because of several drawbacks, including the need for invasive harvesting [4], slow proliferation in vitro [5], and insufficient quantity and quality in older and diseased individuals [6]. A promising alternative is human umbilical cord mesenchymal stem cells (hUCMSCs) [7], which can easily be obtained from the umbilical cord after delivery [8] and which proliferate...
rapidly in vitro and are less immunogenic than BMSCs [9,10]. In addition, hUCMSCs seem to have the similar osteogenic ability as BMSCs [11]. To exploit hUCMSCs for bone therapy, how they differentiate into bone tissue must be clarified.

Many transcriptional pathways and post-transcriptional pathways regulate MSC differentiation [12]. Extensive studies have revealed that long non-coding RNAs (lncRNAs) regulate the differentiation of MSCs [13]. Non-coding RNAs do not code for proteins but play an important role in epigenetic control; they are divided into lncRNAs, which are longer than 200 nucleotides, and microRNAs (miRNAs), which are 18–22 nucleotides long [14]. While miRNAs inhibit translation of mRNAs or trigger their degradation by binding to the 3' untranslated region [15], lncRNAs can interact with DNA, RNA, and protein to regulate gene expression [16–18]. Some lncRNAs affect osteogenesis of BMSCs by regulating Wnt-β-catenin signaling [19] and TGF-β1/Smad3/HDAC signaling [20], as well as by interacting with the miRNAs miR-188 [21] and miR-138 [22]. Besides, several lncRNAs are crucial regulators of MSC osteogenic differentiation [20–23–28]. In contrast, we are unaware of reports linking lncRNAs to osteogenesis of hUCMSCs.

Recent advances in RNA sequencing and bioinformatics allow detailed analysis of non-coding RNAs, making it possible to identify transmitters and receivers in RNA regulatory networks [29]. Therefore, in the present study, we investigated the expression and potential functions of lncRNAs, including lncRNA H19, in the osteogenic differentiation of hUCMSCs. Our findings may help clarify the mechanisms of osteogenic differentiation of hUCMSCs, facilitating the exploitation of hUCMSCs for regenerative bone therapy.

**Materials and methods**

**Cell culture**

hUCMSCs were purchased from Sichuan Neo-life Stem Cell Biotech (Chengdu, China) and cultured in low-glucose Dulbecco’s Modified Eagle Medium (GIBCO, USA) containing 10% fetal bovine serum (GIBCO, USA) and 1% (v/v) penicillin/streptomycin (Hyclone, USA) (hUCMSC growth medium) [4]. We cultured cells in a humidified atmosphere containing 5% CO₂ at 37°C. Cells were detached using 0.25% trypsin (Hyclone, USA) and passaged.

**Osteogenic differentiation of hUCMSCs**

Fourth-passage hUCMSCs were used for osteogenic induction. hUCMSCs with 70–80% confluence were cultured in the osteogenic medium, which contains hUCMSC growth medium plus 10 mM β-glycerol phosphate, 50 μM ascorbic acid, and 100 nM dexamethasone (all from Sigma-Aldrich, USA) [30]. The medium was replaced every two days.

**Alkaline phosphatase (ALP) staining**

We seeded hUCMSCs in 6-well plates at a density of 200,000 cells per well and cultured them in osteogenic medium. We replaced the medium every two days. On day 7, ALP staining was performed using a BCIP/NBT Alkaline Phosphatase Color Development Kit (Beyotime, China) following the instructions from the manufacturer [31]. Briefly, we fixed the cells in 4% paraformaldehyde (Solarbio, China) for 30 min at room temperature (RT), washed the cells three times with PBS (GIBCO, USA), and stained the cells with NBT/BCIP solution for 24 h at RT. Then we removed the staining solution, washed the cells three times with PBS, and observed them under an optical microscope (OLYMPUS, Japan). The ALP staining images were semi-quantified using ImageJ (version 1.6.0, Wayne Rasband, National Institute of Health, USA) as described previously [32,33].

**Alizarin red staining**

We cultured cells the same as for ALP staining and on day 21, we stained the cells with Alizarin red [34]. Briefly, we fixed the cells in 4% paraformaldehyde for 30 min at RT, washed them three times with distilled water, and stained them with 1% Alizarin red staining solution (Solarbio, China) for 30 min at RT. Then we removed the staining solution, washed the cells three times with distilled water, and observed them under an optical
Total RNA isolation and quantitation

We extracted total RNA from hUCMSCs using TRIzol (Invitrogen, USA) following the instructions from the manufacturer [35]. Briefly, we lysed cells in 6-well plates with 1 ml TRIzol per well for 5 min at RT. Then we transferred the lysed cells into an Eppendorf, added 0.2 ml of chloroform, and thoroughly mixed by shaking for 15 sec. After 3 minutes' incubation, we centrifuged the mixture for 15 min at 12,000 g at 4°C. Then the aqueous phase containing the RNA was transferred to a new Eppendorf, 0.5 ml of isopropanol was added, and the tube was incubated for 10 min at 4°C, then centrifuged for 10 min at 12,000 g at 4°C. The pellet containing the RNA was resuspended with 1 ml of 70% RNase-free ethanol and centrifuged at 8,000 rpm for 30 sec. The RNA pellet was air-dried for 10 min and resuspended in 20 μL of RNase-free water. RNA quality and quantity were evaluated using a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA). Only RNA samples with an absorbance ratio 260/280 > 1.8 were analyzed further. RNA integrity and purity were assessed using 1% agarose gel electrophoresis. Quality-checked RNA was stored at −80°C.

Quantitative real-time PCR (qRT-PCR)

qRT-PCR was performed to verify the effectiveness of osteogenic differentiation of hUCMSCs, to validate RNA sequencing, and to confirm IncRNA H19 overexpression. In each case, quality-checked total RNA was reverse-transcribed into cDNA using a RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific), which then served as template to amplify target genes in a Lightcycler96 System (Roche, USA) using Hiieff™ qPCR SYBR® Green Master Mix (YEASEN, China) [36]. Primer sequences for the various target genes are listed in Tables 1 and 2. Amplification was performed with the following cycling conditions: 95°C for 5 min, then 40 cycles of 95°C for 10 sec, 60°C for 20 sec, and 72°C for 20 sec. We quantified levels of target IncRNAs using the 2−ΔΔCq method relative to the level of mRNA encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

RNA sequencing

The isolated total RNA from hUCMSCs on day 7 was sequenced by CloudSeq Biotech (Shanghai, China). Briefly, we removed ribosomal RNA using the RibZero rRNA Removal Kits (Illumina, USA), then used the resulting RNA samples to construct RNA libraries with the TruSeq Stranded Total RNA Library Prep Kit (Illumina, USA). Libraries were assessed quantitatively and qualitatively using the BioAnalyzer 2100 system (Agilent Technologies, USA), then were sequenced using an Illumina HiSeq 4000 sequencer (LC Biotech, China). Paired-end reads from the sequencer were checked for quality using Q30. Raw reads were subjected to 3’ adaptor-trimming, and low-quality reads were removed using Cutadapt software (version 1.9.3) [37]. The resulting high-quality trimmed reads were analyzed for lncRNAs by first mapping them to the human reference genome (UCSC hg19) using Hisat2 software (version 2.0.4) [38], and then assembling and annotating transcripts using Cufflinks (version 2.2.1) [39] based on the Ensembl gtf gene annotation file. Expression of lncRNAs was calculated in terms of fragments per kilobase of exon per million fragments mapped (FPKM).

Functional enrichment analysis

The potential functions of lncRNAs were explored in terms of Gene Ontology functions (www.geneontology.org) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (www.kegg.jp), based on the functions and pathways of coding genes nearest to the lncRNAs [40]. Results were considered significant if associated with P < 0.05.

Construction of the competing endogenous RNA (ceRNA) network

The lncRNA-miRNA-mRNA-associated ceRNA network depicts which lncRNAs and mRNAs compete for the same pool of miRNAs [41]. To
construct this ceRNA network, we combined the lncRNA-miRNA network with the miRNA-mRNA network. First, differentially expressed lncRNAs were named as in the miRcode database, then names of miRNAs were retrieved and the lncRNA-miRNA network was predicted [42]. Next, we generated the miRNA-mRNA network using Targetscan [43], miRTarbase [44], and miRDB [45]. Finally, the ceRNA network was constructed using Cytoscape (version 3.8.2).

**Adenovirus construction and infection of hUCMSCs**

Recombinant adenoviruses were constructed by Hanbio (Shanghai, China) and used to infect hUCMSCs as described [36] at a multiplicity of infection of 10 for 8 h. Cells were infected with viruses encoded the lncRNA H19 or, as a control, green fluorescent protein (GFP). Uninfected cells were used as nonspecific control cells. The cells were incubated inoskeletal medium. On day 3, we extracted total RNA from the cells and performed qRT-PCR to determine the expression of lncRNA H19. On day 7, ALP staining was performed, and total RNA was again extracted and analyzed for expression of ALP, runt-related transcription factor 2 (RUNX2), osteocalcin (OCN), and osteoprotegerin (OPG).

**Statistical analysis**

All experiments were performed at least three times. All statistical analyses were performed using SPSS version 21.0 (SPSS, Chicago, IL, USA). Data were expressed as mean ± standard deviation, and differences between two groups were assessed for significance using the independent-samples t test and one-way ANOVA. Differences associated with *P* < 0.05 were considered significant.

**Results**

In our study, we used RNA sequencing to identify lncRNAs differentially expressed during the osteogenic differentiation of hUCMSCs. After validating the sequencing results using qRT-PCR, we analyzed the potential functions of the differentially expressed lncRNAs based on GO terms and KEGG pathways. Then we used the top 10 upregulated lncRNAs to construct ceRNA networks, and we validated the impact of lncRNA H19 on osteogenic differentiation by overexpressing it in hUCMSCs.

**Table 1.** Primers of internal control and osteogenesis-related markers.

| Gene   | Forward primer sequence(5’-3’) | Reverse primer sequence(5’-3’) | Accession number |
|--------|-------------------------------|-------------------------------|------------------|
| GAPDH  | TGCACCAACAACTGTGCTAGC         | GCCATGACTGTGGTCTATGAG         | NM_001256799.3   |
| ALP    | GACCTCTCTGGGAAAGACATC         | TGAAGGGCTCTTGTCGCTGT          | NM_001127501.4   |
| RUNX2  | TCCACCATTTAGGGACACATC         | TGTAATGCTCTGGTGTTCCA          | NM_00105051.4    |
| OPG    | CGCTGTTGTGTTGAGACATC          | CACACGGTTTCCACCTTGC          | NM_002564.6      |
| OPN    | TGGGAGATGGGTGGTTGTC           | TCTCCCTGGTCGGGTTGG            | NM_001308174.2   |
| OCN    | CCCAGCCGCTACCTGTATCAA         | GGTGACCAACTGTGACAGTC         | NM_000711.1      |

**Table 2.** Primers used for validating sequencing results and confirming lncRNA H19 overexpression.

| Gene   | Forward primer sequence(5’-3’) | Reverse primer sequence(5’-3’) |
|--------|-------------------------------|-------------------------------|
| ENST00000414790 | CTTTCTAGTTGTGCGGGTTGTCG | CGGCTCCTGTCCTTTACTCC |
| ENST00000580476 | CGAGGGTGCGGGCGACATC | CAACACGAGAGGTGGACCT |
| ENST00000577988 | GTTTCGGCTCTGTCTGACG | ACAGAACAAGGAGCCCGAG |
| ENST00000363599 | TGTAGGACACCCAAAACCGC | ACTGAGGACGGGTTCCTTC |
| ENST00000584923 | GTTTCGGGCGGCTGCTTTC | AGACAGAAGGAGCCCGAG |
| NR_027405      | CTAAGGCTAGTTGTGCCAGTC | CCCACCTTCTCTCCTGCC |
| ENST00000428008 | AGTCCCTGGATTGTGTCGG | TCTACTCTACACCCGAT |
| ENST00000484718 | GAGGACACCGTACCGACCCG | ACAGAGTTCGACGGCC |
| ENST00000483140 | CCGACGACCGGCGGCAATA | CTTGCTCTGGGGAACTGAG |
| H19            | CTCCACGGAATTGTCTTCTTCT | CGGCTCCTTTTACTT |

BIOENGINEERED 6883
Osteogenic differentiation of hUCMSCs

The hUCMSCs displayed osteogenic potential in the osteogenic medium. On day 7 after osteogenic induction, staining and semi-quantitative analysis of ALP (Figure 1(a-c)) revealed that the osteogenic medium greatly enhanced ALP activity in comparison to the control. To confirm that cells could properly undergo the late osteogenesis process in the osteogenic medium, we performed Alizarin red staining on day 21 to detect extracellular matrix calcification. Alizarin red staining and semi-quantitative analysis (Figure 1(d-f)) showed that calcium nodule deposits were largely distributed in the osteogenic induced group, while hardly found in the control cultures. The qRT-PCR revealed that the expression levels of ALP, Runx2, and OPN of hUCMSCs were significantly increased after osteogenic induction on day 7 (Figure 1(g-i)). All of these results indicated that hUCMSCs had differentiated

![Figure 1](https://example.com/figure1.png)

Figure 1. Osteogenic differentiation of hUCMSCs. Cultures were either induced to undergo osteogenic differentiation ('induced') or not ('non-induced'). (a-b) ALP staining on day 7. (c) Semi-quantitative analysis of ALP activity on day 7. (d-e) Alizarin red staining on day 21. (f) Semi-quantitative analysis of calcium nodule deposition on day 21. (g-i) Expression levels of the osteogenesis-related markers ALP, RUNX2, and OPN on day 7. ***p < 0.01, ****p < 0.001.
into osteogenic cells induced by the osteogenic medium.

**Expression of differentially expressed IncRNAs**

The profiles of IncRNAs in three cultures that had been osteogenically induced were compared to profiles in three control cultures. Sequencing of RNA from the three induced cultures generated 92289676, 91596000, and 99497528 clean reads, while sequencing from the control cultures generated 74,761,478, 85884244, and 93375536 clean reads (Table 3). In total, 68925 and 28361 unique IncRNAs were identified, respectively, in the induced or control cultures.

After defining differentially expressed IncRNAs as those showing at least a 2-fold change between the two culture conditions \( (P < 0.05) \), we identified 343 differentially expressed IncRNAs, of which 115 were upregulated and 228 were downregulated upon osteogenic induction (Figure 2). The top 20 up- and downregulated transcripts are described in Table 4.

**Validation of RNA sequencing**

To validate the accuracy of the sequencing, we randomly selected five up- and five downregulated IncRNAs and analyzed their expression using qRT-PCR. This assay confirmed that ENST00000414790, ENST00000577988, ENST0000580476, ENST0000584923, and ENST0000363359 were upregulated, while NR_027405, ENST00000428008, ENST00000448718, ENST0000584923, and ENST0000363359 were downregulated.

---

**Table 3. Summary of data from IncRNA-seq for the osteogenic induced groups and non-osteogenic induced groups.**

| Sample Name | Raw reads | fold change | Clean reads | Aligned reads | Unique lncRNAs |
|-------------|-----------|-------------|-------------|---------------|----------------|
| Induced1    | 92,321,904| 92,289,676  | 60,746,205  | 68925         |
| Induced2    | 91,673,540| 91,596,000  | 60,577,213  | 28361         |
| Induced3    | 99,582,072| 99,497,528  | 43,044,724  | 28361         |
| Control1    | 74,813,166| 74,761,478  | 62,836,053  | 28361         |
| Control2    | 85,919,716| 85,884,244  | 60,097,742  | 28361         |
| Control3    | 93,435,824| 93,375,536  | 52,452,845  | 28361         |

---

**Figure 2.** Volcano plot and heat map of differentially expressed IncRNAs. (a) Volcano plot of IncRNAs between hUCMSCs induced to undergo osteogenic differentiation (‘induced’) or not (‘non-induced’). Each point represents a IncRNA. (b) Clustered heatmap of IncRNAs differentially expressed between induced and non-induced cultures. Each column indicates one sample; each row, one IncRNA. The color from blue to red represents increasing expression from low to high. Values are the Z-scores of log2 (FPKM+1), where FPKM refers to fragments per kilobase of exon per million fragments mapped.
Table 4. Details of the top 20 lncRNAs upregulated or downregulated during osteogenic differentiation of hUCMSCs.

| Upregulated | Transcript_id | Gene_id | Fold change | p_value |
|-------------|---------------|---------|-------------|---------|
| ENST00000414790 | ENSG00000130600 | 84.038004 | 0.00005 |
| uc021bpx.2 | AK311497 | 56.460109 | 0.0007 |
| TCONS_00005314 | XLOC_002461 | 5.8994072 | 0.02585 |
| ENST00000418001 | ENSG00000236209 | 5.5513552 | 0.0415 |
| ENST00000426962 | ENSG00000237940 | 5.5510858 | 0.04025 |
| ENST00000606162 | ENSG00000271738 | 5.341111 | 0.00005 |
| ENST00000577988 | ENSG00000265185 | 4.5005771 | 0.0008 |
| ENST00000534671 | ENSG00000246273 | 4.185268 | 0.0123 |
| ENST00000429456 | ENSG00000237940 | 4.117932 | 0.00005 |
| ENST000006024278 | ENSG00000270022 | 4.0364863 | 0.00135 |
| ENST00000571722 | ENSG00000262074 | 3.8309442 | 0.00005 |
| ENST00000430555 | ENSG00000233806 | 3.8303069 | 0.00015 |
| uc003yd.0 | WISP1 | 3.4901039 | 0.00005 |
| ENST00000589987 | ENSG00000261040 | 3.4118367 | 0.01335 |
| ENST0000041570 | ENSG00000237940 | 3.4105559 | 0.0401 |
| uc0011v.3 | INS-IGF2 | 3.3844467 | 0.00005 |
| ENST00000560743 | ENSG00000259450 | 3.341622 | 0.0007 |
| ENST00000540811 | ENSG00000255864 | 3.0725788 | 0.00025 |
| ENST00000426161 | ENSG00000198468 | 3.0506782 | 0.0366 |
| ENST00000602957 | ENSG00000269927 | 3.0294586 | 0.00005 |

| Downregulated | Transcript_id | Gene_id | Fold change | p_value |
|---------------|---------------|---------|-------------|---------|
| uc021bs.1 | EEF1A1 | −57179711 | 0.00215 |
| uc021bs.3 | NBR2 | −20.12588 | 0.0054 |
| ENST00000587182 | ENSG00000272975 | −16.69912 | 0.0001 |
| TCONS_00016279 | XLOC_007654 | −14.77883 | 0.0376 |
| ENST00000423943 | ENSG00000224259 | −10.37457 | 0.00005 |
| ENST00000605886 | ENSG00000272405 | −9.696271 | 0.00205 |
| NR_027405 | MTHFD2 | −8.154916 | 0.00005 |
| uc0011v.3 | AGAP9.2 | −7.727169 | 0.03855 |
| NR_130154 | FARS | −7.36145 | 0.04605 |
| ENST00000602597 | ENSG00000269947 | −7.346668 | 0.0497 |
| ENST00000433753 | ENSG0000012171 | −7.003131 | 0.02515 |
| TCONS_00027719 | XLOC_013282 | −6.955672 | 0.00005 |
| ENST00000533920 | ENSG00000247095 | −6.732069 | 0.0255 |
| ENST00000418368 | ENSG00000215190 | −6.399681 | 0.03775 |
| ENST00000561251 | ENSG00000261824 | −5.520887 | 0.00005 |
| ENST00000607314 | ENSG00000272327 | −5.349522 | 0.00175 |
| ENST00000569291 | ENSG00000261474 | −5.034226 | 0.032 |
| ENST00000324446 | ENSG00000176728 | −4.407498 | 0.049 |
| TCONS_00015147 | XLOC_001790 | −4.376325 | 0.0196 |
| ENST00000602907 | ENSG00000223764 | −4.338451 | 0.00005 |

0.0483140, and NR_109779 were downregulated (Table 5). This agreement suggests that our RNA sequencing is reliable.

Functional enrichment of differentially expressed lncRNAs

The potential roles of differentially expressed lncRNAs in the osteogenic differentiation of hUCMSCs were explored using GO terms and KEGG pathways. A higher enrichment score [-log(P-value), P<0.05] for a given term or pathway indicates a more significant correlation. The potential functions of the differentially expressed lncRNAs with the 10 highest enrichment scores are shown in Figure 3(a-c). Upregulated lncRNAs were most significantly associated with the GO biological process ‘response to fungicide’, ‘cellular component biogenesis’, and ‘RNA metabolic process’; with the GO cellular components ‘intracellular compartment’, ‘intracellular’, and ‘intracellular organelle compartment’; and with the GO molecular functions ‘binding’, ‘ion binding’, and ‘protein binding’. We identified 49 KEGG pathways that were significantly related to differentially expressed lncRNAs, of which 38 pathways were upregulated and 11 were downregulated after osteogenic induction. The upregulated pathways with the 10 highest enrichment scores are shown in Figure 3(d). The KEGG pathways most significantly associated with lncRNAs were ‘phosphatidylinositol signaling system’, ‘aldosterone synthesis and secretion’, and ‘inositol phosphate metabolism’.

Construction of the ceRNA network of interacting lncRNAs, miRNAs, and mRNAs

lncRNAs can bind to miRNAs and thereby prevent the latter from binding to their target mRNA and inhibiting its translation. To predict the lncRNA-miRNA-mRNA interactions of the differentially expressed lncRNAs, lncRNA-miRNA-mRNA-associated ceRNA networks were constructed. We constructed six ceRNA networks based on the top 10 upregulated lncRNAs (Table 6): ENST00000414790, uc021bpx.2, TCONS_0005314, ENST00000418001, ENST00000426962, ENST00000606162, ENST00000577988, ENST00000534671, ENST00000429456, and ENST0000602478 (Figure 4). Among these lncRNAs, ENST00000414790 and uc021bpx.2 differed between induced and control cultures several-fold more than the eight other lncRNAs did. The Ensembl database indicated that for both of these lncRNAs, the full-length transcript was lncRNA H19, with ENST00000414790 accounting for the largest number of transcripts from H19. Thus, we chose lncRNA H19 to explore its potential regulatory role in the osteogenic differentiation of hUCMSCs.
Overexpression of lncRNA H19 enhances osteogenic differentiation of hUCMSCs

Our RNA sequencing and qRT-PCR results showed upregulation of the lncRNA H19 at seven days after osteogenic differentiation of hUCMSCs (Table 5). To confirm the effect of lncRNA H19 on osteogenesis, we overexpressed lncRNA H19 in hUCMSCs using recombinant adenovirus. Overexpression of lncRNA H19 was confirmed by qRT-PCR on day 3 after infection (Figure 5(a)). On day 7 after infection, ALP staining and semi-quantitative analysis revealed that ALP activity in lncRNA H19 overexpressed hUCMSCs was greatly enhanced in comparison to the hUCMSCs infected with control adenovirus (Figure 5(b,c)). The qRT-PCR results from day 7 indicated that lncRNA H19 overexpressed hUCMSCs had a significantly higher expression of the osteogenic markers ALP, RUNX2, OCN, and OPG than hUCMSCs infected with control adenovirus (Figure 5(d-g)). These results suggest that the lncRNA H19 helps drive osteogenic differentiation of hUCMSCs.

Table 5. Comparison of results from qRT-PCR and RNA sequencing.

| Gene          | qRT-PCR | RNA sequencing |
|---------------|---------|---------------|
|               | Fold change | p_value | Fold change | p_value |
| ENST00000414790 | 132.3     | <0.0001     | 84.038004 | 0.00005 |
| ENST00000577988 | 1.432     | 0.0475      | 4.5005771 | 0.0008  |
| ENST00000580476 | 1.97      | 0.0188      | 2.7522662 | 0.00005 |
| ENST00000584923 | 2.349     | 0.0156      | 2.1880565 | 0.0287  |
| ENST00000363359 | 1.278     | 0.0064      | 2.0832269 | 0.00005 |
| NR_027405      | -1.772    | 0.0045      | -8.154916 | 0.00005 |
| ENST00000428008 | -1.243   | 0.0065      | -3.774093 | 0.0029  |
| ENST00000448718 | -1.431    | 0.0347      | -2.674149 | 0.00005 |
| ENST00000483140 | -1.266   | 0.0073      | -2.463774 | 0.0017  |
| NR_109779      | -1.524    | 0.002       | -2.161331 | 0.00005 |

Figure 3. Enrichment of differentially expressed IncRNAs in GO terms and KEGG pathways. GO terms: (a) Biological processes, (b) cellular components, and (c) molecular functions. (d) KEGG pathways.
Regeneration of bone defects caused by tumor resection, infection, and trauma is a clinical challenge for orthopedic surgeons [46]. To treat these defects, bone grafting materials including autologous bone grafts (autografts), allogenic bone grafts (allografts), and synthetic grafts have been extensively investigated [1]. Autografts are considered the gold standard to treat bone defects because of

### Table 6. Filtered differentially expressed IncRNAs.

| Transcript_id | Gene_id         | Fold change | p_value     | Regulation | IncRNA_source   |
|---------------|-----------------|-------------|-------------|------------|----------------|
| ENST00000414790 | ENSG00000130600 | 84.04       | 0.00005     | up         | Ensembl        |
| uc021qb.x.2    | AK311497        | 56.46       | 0.0007      | up         | UCSC_knowngene |
| TCONS_00005314 | XLOC_002461     | 5.9         | 0.0258      | up         | TCONS          |
| ENST00000418001 | ENSG00000236209 | 5.55       | 0.0415      | up         | Ensembl        |
| ENST00000426962 | ENSG00000237940 | 5.55       | 0.04025     | up         | Ensembl        |
| ENST00000606162 | ENSG00000271738 | 5.34       | 0.00005     | up         | Ensembl        |
| ENST00000577988 | ENSG00000265185 | 4.5        | 0.0008      | up         | Ensembl        |
| ENST00000534671 | ENSG00000246273 | 4.19       | 0.0123      | up         | Ensembl        |
| ENST00000429456 | ENSG00000237940 | 4.12       | 0.00005     | up         | Ensembl        |
| ENST00000602478 | ENSG00000270022 | 4.04       | 0.00135     | up         | Ensembl        |

Figure 4. Construction of the ceRNA network describing IncRNA-miRNA-mRNA interactions during osteogenic differentiation of hUCMSCs.

### Discussion

Regeneration of bone defects caused by tumor resection, infection, and trauma is a clinical challenge for orthopedic surgeons [46]. To treat these defects, bone grafting materials including autologous bone grafts (autografts), allogenic bone grafts (allografts), and synthetic grafts have been extensively investigated [1]. Autografts are considered the gold standard to treat bone defects because of
their osteoconduction and osteoinduction. However, autografting suffers from several major disadvantages including donor site morbidity and limited bone supply [47]. Allografts and synthetic grafts can avoid the drawbacks of autografts. However, allografts have several disadvantages of their own, including bacterial infection and disease transmission, while synthetic grafts integrate poorly with host bone and are susceptible to wear and tear [48,49].

To find alternative therapies to treat bone defects, cell-based tissue engineering using scaffolds seeded with cells to promote bone regeneration has been suggested [2]. BMSCs can easily be harvested from bone marrow and are regarded as the ‘gold standard’ among MSCs [50]. Therefore, BMSCs are widely used in bone tissue engineering and cell-based therapies as cytokine pumps and replacement cells [5]. However, BMSCs must be harvested through an invasive procedure, and relatively few cells can be recovered from each patient [4]. Moreover, their slow proliferation means that several weeks are needed to expand them in vitro before clinical use [5]. In addition, BMSCs from older and diseased individuals show lower quantity and quality [51]. Therefore, alternative MSC sources are needed for tissue engineering.

hUCMSCs have been suggested as an excellent alternative source of MSCs for bone regeneration [7]. Unlike BMSCs, hUCMSCs can be collected noninvasively, proliferate rapidly, and show higher differentiation capability [8–10]. Whereas BMSCs show notably longer doubling time after the sixth passage [52], hUCMSCs maintain a steady doubling time until the tenth passage. hUCMSCs are also less immunogenic than hBMSCs because they do not express costimulatory ligands including CD86, CD80, or CD40, they do not express...

Figure 5. Overexpression of the lncRNA H19 enhances osteogenic differentiation of hUCMSCs. Cultures of hUCMSCs were uninfected (nonspecific control, ‘NC’) or infected with recombinant adenovirus expressing GFP (‘Ad-GFP’) or IncRNA H19 (‘Ad-H19’). (a) qRT-PCR results from day 3 confirmed the overexpression of IncRNA H19. (b) ALP staining on day 7. (c) Semi-quantitative analysis of ALP activity on day 7. (d-g) Expression of osteogenic markers ALP, RUNX2, OCN, and OPG after osteogenic induction on day 7. *P < 0.05, **P < 0.01, ***P < 0.001.
major histocompatibility complex (MHC) class II molecules, and they express only low levels of MHC class I molecules [53]. All these advantages render hUCMSCs attractive for cell-based bone tissue engineering.

Before hUCMSCs can be exploited for regenerative bone therapy, the regulation of their osteogenic differentiation needs to be understood. Physical, chemical, and biological signals can influence MSC differentiation via a batch of signaling pathways, which ultimately trigger regulatory cascades at both the transcriptional and post-transcriptional levels [12,54]. It has been reported that many critical signaling pathways help regulate MSC differentiation, such as pathways involving Hedgehog, Notch, Wnt, and TGF-β/BMP [12]. And IncRNAs may help regulate these pathways, since IncRNAs have been shown to exert crucial roles in many biological and pathological processes, including metabolism, cellular development, tumorogenesis, immune response, and genetic imprinting [55]. Besides, it has been demonstrated that IncRNAs regulate the differentiation of MSCs [13], including their osteogenic differentiation [20,23–28]. In recent years, the expression profiles and functions of IncRNAs in the osteogenic differentiation of hBMSCs have been investigated [23,40,56,57]. However, the role of IncRNAs in hUCMSC osteogenic differentiation remains largely unknown.

The present study first revealed the expression profiles of IncRNAs during the osteogenic differentiation of hUCMSCs and further analyzed these IncRNAs using bioinformatic analyses. We identified 343 IncRNAs differentially expressed during osteogenic differentiation, of which 115 were upregulated and 228 were downregulated. To validate the accuracy of the sequencing-based results, 10 differentially expressed IncRNAs were analyzed by qRT-PCR. The qRT-PCR results obtained from these 10 IncRNAs were consistent with the sequencing results, demonstrating that the sequencing results were reliable. The potential functions of differentially expressed IncRNAs were explored by searching for enrichment in GO terms and KEGG pathways. GO analysis showed that the main GO terms were found to be associated with the cellular component, such as intracellular part, intracellular, intracellular organelle part, and organelle part. The KEGG pathways analysis indicated that many pathways such as ‘phosphatidylinositol signaling system’, ‘aldosterone synthesis and secretion’, and ‘inositol phosphate metabolism’ may be involved in the osteogenic differentiation of hUCMSCs. Among these pathways, the phosphatidylinositol signaling system is closely related to bone metabolism. It has been reported that activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway could mediate osteogenic differentiation of MSCs [58]. Besides, the majority of the phosphatidylinositol family including PI3K plays a regulatory role in the osteogenesis of MSCs by the regulation of BMP-2 gene expression via mitogen-activated protein kinases signaling pathway [59,60].

To predict some core regulating factors in the osteogenic differentiation of hUCMSCs, we then chose the top 10 upregulated IncRNAs to construct potential interactions between IncRNA, miRNAs, and mRNAs by ceRNA networks. In the present study, we found the full-length transcript of the top 2 upregulated IncRNAs (ENST00000414790 and uc021qbx.2) was IncRNA H19. Thus, we chose IncRNA H19 to explore its potential regulatory role in the osteogenic differentiation of hUCMSCs. Our study showed that IncRNA H19 upregulation resulted in increased ALP activity and higher expression of the osteogenic markers ALP, RUNX2, OCN, and OPB in hUCMSCs, suggesting IncRNA H19 was regulating the osteogenic differentiation of hUCMSCs as an enhancer. The IncRNA H19 is one of the most well-known conserved non-coding transcripts expressed from the maternal allele [61]. It has been demonstrated that IncRNA H19 presents a significant role in mediating the osteogenesis of MSCs [62]. IncRNA H19 was reported to be upregulated in the osteogenic differentiation of hBMSCs in several studies [20,23,63]. However, another study in human adipose-derived stem cells got the reverse trend, which may be explained by the differential tissue- and cell-specific expression manner of IncRNA H19 during embryogenesis [64]. Besides, Huang et al reported that IncRNA H19 promoted osteogenesis of hBMSCs via the TGF-β1/Smad3/HDAC pathway, and miR-675 partially mediated this pro-osteogenic function [20]. Meanwhile, Liang et al
demonstrated that lncRNA H19 functioned as a ceRNA for miR-141 and miR-22 to direct potentiate the Wnt/β-catenin pathway, leading to the enhancement of osteogenesis of hBMSCs [63]. Moreover, lncRNA H19 could also up-regulate focal adhesion kinase by serving as a ceRNA for miR-138 to promote tension-induced osteogenic differentiation of hBMSCs [65]. In addition, an in vitro study of mice reported that lncRNA H19 mediated the expression level of ligand-dependent corepressor by acting as a ceRNA for miR-188, thus regulating the balance between osteogenic and adipogenic differentiation of BMSCs [21]. Overall, these studies demonstrated that the lncRNA H19-mediated lncRNA-miRNA-mRNA regulatory axis plays an important role in mediating the osteogenesis of MSCs. Therefore, the underlying ceRNA mechanisms of lncRNA H19 in regulating the osteogenesis of hUCMSCs are needed to be further clarified.

Nevertheless, our findings should be treated with caution in light of several limitations. First, we profiled lncRNA expression and observed the expression of gene markers during early osteogenic differentiation; such profiling and observation should also be performed at a late stage of the osteogenesis process. Second, we applied only one approach when constructing the ceRNA network of lncRNA-miRNA-mRNA interactions; using multiple approaches may provide a more accurate result. Third, our sample was small, so our results should be verified and extended in studies with more samples.

Conclusion

This appears to be the first report of lncRNA expression profiles during the osteogenic differentiation of hUCMSCs. We explored potential functions of differentially expressed lncRNAs based on enrichment in GO terms and KEGG pathways. We also predicted the ceRNA network of interactions among lncRNAs, miRNAs, and mRNAs. In particular, we identified the lncRNA H19 as a potential driver of osteogenic differentiation of hUCMSCs. These findings provide numerous testable hypotheses to guide experiments to elucidate how lncRNAs, miRNAs, and mRNAs regulate the osteogenic differentiation of hUCMSCs.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was financially supported by the National Natural Science Foundation of China (81771049) and the Department of Science and Technology of Sichuan Province (2020YJ0228).

Data availability statement

Data is available at NCBI Sequence Read Archive (SRA, https://www.ncbi.nlm.nih.gov/sra) database, accession numbers: SRX10504596, SRX10504598, SRX10504600, SRX10504602, SRX10504604, SRX10504606.

ORCID

Wenchuan Chen http://orcid.org/0000-0002-6145-7878

References

[1] Garcia-Gareta E, Coathup MJ, Blunn GW. Osteoinduction of bone grafting materials for bone repair and regeneration. Bone. 2015;81:112–121.
[2] Jr P, Kouourpis D, Dj L, et al. Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects. Front Bioeng Biotechnol. 2018;6:105.
[3] Arthur A, Gronthos S. Clinical Application of Bone Marrow Mesenchymal Stem/Stromal Cells to Repair Skeletal Tissue. Int J Mol Sci. 2020;21(24):24.
[4] Chen W, Liu J, Manuchehrabadi N, et al. Umbilical cord and bone marrow mesenchymal stem cell seeding on macroporous calcium phosphate for bone regeneration in rat cranial defects. Biomaterials. 2013;34(38):9917–9925.
[5] Diao Y, Ma Q, Cui F, et al. Human umbilical cord mesenchymal stem cells: osteogenesis in vivo as seed cells for bone tissue engineering. J Biomed Mater Res A. 2009;91A(1):123–131.
[6] Lu R, Sun J, Li H, et al. Microenvironment Influences on Human Umbilical Cord Mesenchymal Stem Cell-Based Bone Regeneration. Stem Cells Int. 2021;2021:4465022.
[7] de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012;367(24):2305–2315.
[8] Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells. 2003;21(1):105–110.

[9] Zhao J, Yu G, Cai M, et al. Bibliometric analysis of global scientific activity on umbilical cord mesenchymal stem cells: a swiftly expanding and shifting focus. Stem Cell Res Ther. 2018;9(1):32.

[10] Weiss ML, Anderson C, Medcetty S, et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells. 2008;26(11):2865–2874.

[11] Schneider RK, Puelles L, Kramann R, et al. The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal stem cells and matrix remodelling in three-dimensional collagen scaffolds. Biomaterials. 2010;31(3):467–480.

[12] Chen Q, Shou P, Zheng C, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 2016;23(7):1128–1139.

[13] Hu S, Shan G. LncRNAs in Stem Cells. Stem Cells Int. 2016;2016:2681925.

[14] Moran VA, Perera RJ, Khalil AM. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res. 2012;40(14):6391–6400.

[15] Liu Y, Xu L, Lu B, et al. LncRNA H19/microRNA-675/PPARa axis regulates liver cell injury and energy metabolism remodelling induced by hepatitis B X protein via Akt/mTOR signalling. Mol Immunol. 2019;116:18–28.

[16] Qi W, Song X, Li L. Long non-coding RNA-guided regulation in organisms. Sci China Life Sci. 2013;56(10):891–896.

[17] Chen L, Kostadima M, Martens JHA, et al. Transcriptional diversity during lineage commitment of human blood progenitors. Science (New York, NY). 2014;345(6204):1251033.

[18] Pefanis E, Wang J, Rothschild G, et al. Noncoding RNA transcription targets AID to divergently transcribed loci in B cells. Nature. 2014;514(7522):389–393.

[19] Zhou P, Li Y, Di R, et al. H19 and Foxc2 synergistically promotes osteogenic differentiation of BMSCs via Wnt-β-catenin pathway. J Cell Physiol. 2019;234(8):13799–13806.

[20] Huang Y, Zheng Y, Jia L, et al. Long Noncoding RNA H19 Promotes Osteoblast Differentiation Via TGF-β1/Smad3/HDAC Signaling Pathway by Deriving miR-675. Stem Cells. 2015;33(12):3481–3492.

[21] Wang Y, Liu W, Liu Y, et al. Long noncoding RNA H19 mediates LCoR to impact the osteogenic and adipogenic differentiation of mBMSCs in mice through sponging miR-188. J Cell Physiol. 2018;233(9):7435–7446.

[22] Zhou QP, Zhang F, Zhang J, et al. H19 promotes the proliferation of osteocytes by inhibiting p53 during fracture healing. Eur Rev Med Pharmacol Sci. 2018;22(8):2226–2232.

[23] Wang L, Wang Y, Li Z, et al. Differential expression of long noncoding ribonucleic acids during osteogenic differentiation of human bone marrow mesenchymal stem cells. Int Orthop. 2015;39(5):1013–1019.

[24] Jia Q, Jiang W, Ni L. Down-regulated non-coding RNA (lncRNA-ANCR) promotes osteogenic differentiation of periodontal ligament stem cells. Arch Oral Biol. 2015;60(2):234–241.

[25] Li H, Zhang Z, Chen Z, et al. Osteogenic growth peptide promotes osteogenic differentiation of mesenchymal stem cells mediated by LncRNA AKR141205-induced upregulation of CXCL13. Biochem Biophys Res Commun. 2015;466(1):82–88.

[26] Zhuang W, Ge X, Yang S, et al. Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells From Multiple Myeloma Patients By Targeting BMP4 Transcription. Stem Cells. 2015;33(6):1985–1997.

[27] Zhang Y, Chen B, Li D, et al. LncRNA NEAT1/miR-29b-3p/BMP1 axis promotes osteogenic differentiation in human bone marrow-derived mesenchymal stem cells. Pathol Res Pract. 2019;215(3):525–531.

[28] Liu Z, Xu S, Dao J, et al. Differential expression of lncRNA/miRNA/mRNA and their related functional networks during the osteogenic/odontogenic differentiation of dental pulp stem cells. J Cell Physiol. 2020;235(4):3350–3361.

[29] Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15(suppl_1):R17–29.

[30] Rong Q, Li S, Zhou Y, et al. A novel method to improve the osteogenesis capacity of hUCMSCs with dual-directional pre-induction under screened co-culture conditions. Cell Prolif. 2020;53(2):e12740.

[31] Ge X, Li Z, Jing S, et al. Parathyroid hormone enhances the osteo/odontogenic differentiation of dental pulp stem cells via ERK and P38 MAPK pathways. J Cell Physiol. 2020;235(2):1209–1221.

[32] Jiang HT, Deng R, Deng Y, et al. The role of Serpina3n in the reversal effect of ATRA on dexamethasone-inhibited osteogenic differentiation in mesenchymal stem cells. Stem Cell Res Ther. 2021;12(1):291.

[33] Smieszek A, Marcinkowska K, Pielok A, et al. The Role of miR-21 in Osteoblasts-Osteoclasts Coupling In Vitro. Cells. 2020;9(2):2.

[34] Jin C, Jia L, Tang Z, et al. Long non-coding RNA MIR22HG promotes osteogenic differentiation of bone marrow mesenchymal stem cells via PTEN/AKT pathway. Cell Death Dis. 2020;11(7):601.
[35] Li Z, Sun Y, He M, et al. Differentially-expressed mRNAs, microRNAs and long noncoding RNAs in intervertebral disc degeneration identified by RNA-sequencing. Bioengineered. 2021;12(1):10 26–1039.

[36] Su C, Zheng X, He Y, et al. Transcriptomic profiling and functional prediction reveal aberrant expression of circular RNAs during osteogenic differentiation in human umbilical cord mesenchymal stromal cells. Sci Rep. 2021;11(1):19881.

[37] Kechin A, Boyarskikh U, Kel A, et al. cutPrimers: a New Tool for Accurate Cutting of Primers from Reads of Targeted Next Generation Sequencing. J Comput Biol. 2017;24(11):1138–1143.

[38] Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12(4):357–360.

[39] Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28 (5):511–515.

[40] Qiu X, Jia B, Sun X, et al. The Critical Role of Long Noncoding RNA in Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells. Biomed Res Int. 2017;2017:5045827.

[41] Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–352.

[42] Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics. 2012;28 (15):2062–2063.

[43] Agarwal V, Bell GW, and Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4 :e05005.

[44] Hsu SD, Lin FM, Wu WY, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39(suppl_1):D163–169.

[45] Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127–d131.

[46] Shi Z, Xu Y, Mulatibieke R, et al. Nano-Silicate-Reinforced and SDI-1α-Loaded Gelatin-Methacryloyl Hydrogel for Bone Tissue Engineering. Int J Nanomedicine. 2020;15:9337–9353.

[47] Zhang J, Liu W, Schnitzler V, et al. Calcium phosphate cements for bone substitution: chemistry, handling and mechanical properties. Acta Biomater. 2014;10(3):1035–1049.

[48] Salgado AJ, Coutinho OP, Reis RL. Bone tissue engineering: state of the art and future trends. Macromol Biosci. 2004;4(8):743–765.

[49] Rolvien T, Barbeck M, Wenisch S, et al. Cellular Mechanisms Responsible for Success and Failure of Bone Substitute Materials. Int J Mol Sci. 2018;19 (10):10.

[50] Cao Y, Gang X, Sun C, et al. Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer. J Diabetes Res. 2017;2017:9328347.

[51] Ma Y, Qi M, An Y, et al. Autophagy controls mesenchymal stem cell properties and senescence during bone aging. Aging Cell. 2018;17(1):1.

[52] Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91(8):10 17–1026.

[53] Batsali AK, Kastrinaki MC, Papadaki HA, et al. Mesenchymal stem cells derived from Wharton’s jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther. 2013;8(2):144–155.

[54] Tang QQ, Lane MD. Adipogenesis: from stem cell to adipocyte. Annu Rev Biochem. 2012;81(1):715–736.

[55] Perry RB, Ulitsky I. The functions of long noncoding RNAs in development and stem cells. Development. 2016;143(21):3882–3894.

[56] Zhang W, Dong R, Diao S, et al. Differential long noncoding RNA/mRNA expression profiling and functional network analysis during osteogenic differentiation of human bone marrow mesenchymal stem cells. Stem Cell Res Ther. 2017;8(1):30.

[57] Sun X, Jia B, Qiu XL, et al. Potential functions of long non-coding RNAs in the osteogenic differentiation of human bone marrow mesenchymal stem cells. Mol Med Rep. 2019;19(1):103–114.

[58] Song F, Jiang D, Wang T, et al. Mechanical Stress Regulates Osteogenesis and Adipogenesis of Rat Mesenchymal Stem Cells through PI3K/Akt/GSK-3β/β-Catenin Signaling Pathway. Biomed Res Int. 2017;2017:6027402.

[59] Osyczka AM, Leboy PS. Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling. Endocrinology. 2005;146 (8):3428–3437.

[60] Lee SU, Shin HK, Min YK, et al. Emodin accelerates osteoblast differentiation through phosphatidylinositol 3-kinase activation and bone morphogenetic protein-2 gene expression. Int Immunopharmacol. 2008;8 (5):741–747.

[61] Gabory A, Ripoche MA, Le Digarcher A, et al. H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. Development. 2009;136 (20):3413–3421.
[62] Li D, Yang C, Yin C, et al. LncRNA, Important Player in Bone Development and Disease. Endocr Metab Immune Disord Drug Targets. 2020;20(1):50–66.

[63] Liang WC, Fu WM, Wang YB, et al. H19 activates Wnt signaling and promotes osteoblast differentiation by functioning as a competing endogenous RNA. Sci Rep. 2016;6(1):20121.

[64] Huang G, Kang Y, Huang Z, et al. Identification and Characterization of Long Non-Coding RNAs in Osteogenic Differentiation of Human Adipose-Derived Stem Cells. Cell Physiol Biochem. 2017;42(3):1037–1050.

[65] Wu J, Zhao J, Sun L, et al. Long non-coding RNA H19 mediates mechanical tension-induced osteogenesis of bone marrow mesenchymal stem cells via FAK by sponging miR-138. Bone. 2018;108:62–70.